HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Trading 02-25 10:54:16

68.650

-1.350

-1.93%

High71.000	Low68.400	Vol72.20K
Open70.500	D1 Closing70.000	Amplitude3.71%
Mkt Cap37.28B	Tradable Cap23.76B	Total Shares543.00M
T/O5.00M	T/O Rate0.02%	Tradable Shares346.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":68.65,"timestamp":1771988044747,"preClose":70,"halted":0,"volume":72200,"delay":0,"changeRate":-0.019285714285714205,"floatShares":346074397,"shares":543000000,"eps":1.509618,"marketStatus":"Trading","change":-1.35,"latestTime":"02-25 10:54:16","open":70.5,"high":71,"low":68.4,"amount":5003102,"amplitude":0.037143,"askPrice":68.75,"askSize":1000,"bidPrice":68.65,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.661924,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1771992000000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":70,"openAndCloseTimeList":[[1771983000000,1771992000000],[1771995600000,1772006400000]],"volumeRatio":0.475566,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/wiki","defaultTab":"wiki","newsList":[{"id":"1162604981","title":"Shanghai Henlius Biotech (2696) Amends Agreements with KGBio and Abbott, Expands HANSIZHUANG Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=1162604981","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162604981?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:01","pubTimestamp":1771923699,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (2696) entered a partial termination agreement with PT Kalbe Genexine Biologics (KGBio), withdrawing exclusive license rights for the anti-PD-1 monoclonal antibody...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1175106036","title":"HENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio","url":"https://stock-news.laohu8.com/highlight/detail?id=1175106036","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175106036?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:00","pubTimestamp":1771923627,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000320264.USD","02696","BK1161","HK0000306685.HKD","HK0000165453.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2613796555","title":"Shanghai Henlius expands HANSIZHUANG licensing partnership with Abbott","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796555","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613796555?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:52","pubTimestamp":1771923158,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has expanded its collaboration with Abbott by amending their license agreement for HANSIZHUANG . Abbott gains exclusive commercialization rights across additional territories spanning Asia, the Middle East, Africa and Eastern Europe , in addition to its previously agreed Latin America and Caribbean markets. The expanded deal includes up to US$46 million in additional regulatory milestones and up to US$80 million in additional sales milestones payable to Henlius.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 24, 2026, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLbLHhzJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320264.USD","HK0000320223.HKD","02696","00656","HK0000306701.USD","BK1230"],"gpt_icon":0},{"id":"2611483621","title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483621","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483621?lang=en_us&edition=fundamental","pubTime":"2026-02-16 19:11","pubTimestamp":1771240274,"startTime":"0","endTime":"0","summary":"Why Shanghai Henlius Biotech Is On Investors’ Radar\nShanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns.\nSee our latest analysis for Shanghai Henlius Biotech.\nAt the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","DCF","HK0000306701.USD","HK0000306685.HKD","02696","BK4585","HK0000320223.HKD","LABU","HK0000320264.USD","BK4588","HK0000165453.HKD"],"gpt_icon":0},{"id":"1189628706","title":"Shanghai Henlius Biotech, Inc. (2696) Announces FDA Approval of HLX15-SC IND for Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=1189628706","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189628706?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:42","pubTimestamp":1771216969,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (2696) recently received approval from the United States Food and Drug Administration for an investigational new drug (IND) application to conduct a phase 1 clinical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1113363482","title":"HENLIUS's HLX15-SC for Multiple Myeloma Receives FDA Clearance for Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1113363482","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113363482?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:40","pubTimestamp":1771216822,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the Investigational New Drug (IND) application for the Phase 1 clinical trial of its self-developed HLX15-SC (recombinant fully human anti-CD38 monoclonal antibody...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320264.USD","02696","BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2611080481","title":"FDA Approves IND Application for Shanghai Henlius Biotech HLX15-SC in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2611080481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611080481?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:31","pubTimestamp":1771216272,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its investigational new drug  application for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection  for the treatment of multiple myeloma, has been approved by the United States Food and Drug Administration  for a phase 1 clinical trial. The company independently developed HLX15-SC and has also entered into an agreement to commercialize HLX15 in both subcutaneous and intravenous forms in the United States and agreed European countries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL6rwJtS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD","00656","BK1230","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2611108063","title":"Shanghai Henlius Biotech  - FDA Approves Ind Application for Hlx15-Sc for Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2611108063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611108063?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:31","pubTimestamp":1771216268,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nFWN3Z91TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000320264.USD","HK0000306701.USD","HK0000165453.HKD","HK0000306685.HKD","02696","HK0000320223.HKD"],"gpt_icon":0},{"id":"1142401139","title":"Shanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=1142401139","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142401139?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:00","pubTimestamp":1770886840,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2610943249","title":"Shanghai Henlius Biotech Inc - Investigational New Drug Application of Hlx15-Sc for Treatment of Multiple Myeloma Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2610943249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610943249?lang=en_us&edition=fundamental","pubTime":"2026-02-12 16:50","pubTimestamp":1770886204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","BK1161","HK0000320264.USD","HK0000306685.HKD","02696"],"gpt_icon":0},{"id":"2610943791","title":"Shanghai Henlius Biotech Receives NMPA Approval for HLX15-SC IND Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2610943791","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610943791?lang=en_us&edition=fundamental","pubTime":"2026-02-12 16:49","pubTimestamp":1770886193,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration  has approved the investigational new drug  application for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection intended for subcutaneous administration, for the treatment of multiple myeloma. The IND approval allows the company to proceed with a phase 1 clinical trial of HLX15-SC, which has been independently developed by Shanghai Henlius Biotech Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 12, 2026, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL3NnjKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000165453.HKD","BK1161","BK1230","00656","HK0000306701.USD"],"gpt_icon":0},{"id":"1190194966","title":"Shanghai Henlius Biotech (2696) Announces First Patient Dosed in HLX43 Combination Trial for Advanced Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1190194966","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190194966?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:29","pubTimestamp":1770802181,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (2696) recently announced that the first patient has been dosed in a Phase 1b/2 clinical study evaluating HLX43 (an anti-PD-L1 antibody-drug conjugate) in combination with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1143055634","title":"HENLIUS (02696) Doses First Patient in China for Phase 1b/2 Trial of HLX43 Combined with HLX07 or Hansizhuang® in Advanced/Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1143055634","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143055634?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:06","pubTimestamp":1770800794,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1b/2 clinical study. The trial is evaluating the combination of HLX43 (a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320264.USD","HK0000165453.HKD","HK0000306685.HKD","02696","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2610987653","title":"Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610987653","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610987653?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:00","pubTimestamp":1770800459,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has announced the dosing of the first patient in a phase 1b/2 clinical study evaluating HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with either HLX07  or HANSIZHUANG  in patients with advanced or metastatic colorectal cancer in mainland China. The study is designed to assess the safety, tolerability, and efficacy of the combination therapies. The trial includes a safety run-in stage with dose escalation, followed by a dose expansion stage. As of the date of the announcement, no results from the study have been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL7pXq3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD","00656","BK1161","BK1230"],"gpt_icon":0},{"id":"1189591344","title":"HENLIUS Shares Surge Over 6% Again, Climbing More Than 24% This Month on Japanese Rights Deal for Serplulimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1189591344","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189591344?lang=en_us&edition=fundamental","pubTime":"2026-02-10 11:28","pubTimestamp":1770694136,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise over 6% again, bringing its cumulative increase for the month to more than 24%. At the time of writing, the stock was up 5.67%, trading at HKD 70.85 with a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000306685.HKD","BK4585","HK0000165453.HKD","HK0000320223.HKD","VT","BK1161","HK0000320264.USD","BK4588","02696","VXUS"],"gpt_icon":0},{"id":"1133857400","title":"Goldman Sachs: Mainland Healthcare Sector Returns to Hinge on Data and Earnings Visibility This Year, CDMO Firms Favored","url":"https://stock-news.laohu8.com/highlight/detail?id=1133857400","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133857400?lang=en_us&edition=fundamental","pubTime":"2026-02-09 14:17","pubTimestamp":1770617841,"startTime":"0","endTime":"0","summary":"According to a research report from Goldman Sachs, the strong trends observed in the mainland healthcare sector last year are expected to continue into this year. However, investors are increasingly...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","HK0000165453.HKD","02359","HK0000306685.HKD","SG9999014674.SGD","BK1191","BK1161","BK1583","BK1141","BK1589","159891","LU0052750758.USD","03692","02696","BK4139","HK0000306701.USD","BK1576","LU0320764599.SGD","LU0708995583.HKD","LU2488822045.USD","LU1046422090.SGD","CDMO","02268","HK0000320223.HKD","06990","LU2045819591.USD","LU2125910500.SGD","HK0000320264.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"1102736592","title":"HENLIUS Shares Climb Over 5% on Licensing Deal with Eisai for Japan Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=1102736592","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102736592?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:16","pubTimestamp":1770344182,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise more than 5% in morning trading. At the time of writing, the stock was up 4.64%, trading at HK$63.15 with a turnover of HK$32.62 million. The increase follows an...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","BK4588","HK0000306685.HKD","VT","BK4585","VXUS","BK1161","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2609371290","title":"Eisai and Henlius Enter Into Exclusive Commercial License Agreement for Anti-Pd-1 Antibody Serplulimab in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2609371290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609371290?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:45","pubTimestamp":1770291906,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA4CSBFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","HK0000306701.USD","BK1161","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","02696"],"gpt_icon":0},{"id":"2609226371","title":"Shanghai Henlius Biotech Inc - Plans 2026 Application for Es-Sclc in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2609226371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609226371?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:45","pubTimestamp":1770291906,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA4CSBFC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"1196755692","title":"Shanghai Henlius Biotech (2696) and Eisai Sign License Agreement for HANSIZHUANG in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=1196755692","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196755692?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:07","pubTimestamp":1770282456,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (2696) entered into a license agreement with Eisai Co., Ltd. on February 5, 2026, granting Eisai the rights to develop, manufacture, and commercialize HANSIZHUANG...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.1935},{"period":"3month","weight":0.0219},{"period":"6month","weight":-0.0541},{"period":"1year","weight":2.1891},{"period":"ytd","weight":0.227}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.006},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.1392},{"period":"ytd","weight":0.0374}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.125049},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}